Contraview.Bio (@Contraview_Bio) header
Contraview.Bio (@Contraview_Bio) profile picture

Biotech research for investors and founders. Drug targets, clinical progress and company outcomes. Evidence over hype.

Boston, MA
Joined April 2024
Does target crowding matter in biotech? Phase 2 drugs with a rival in trials for the same target and disease were 2.5x as likely to reach Phase 3. With 12+ rivals on a target, the adjusted acquisition rate was about half. No clear IPO link. contraview.bio/research/how-…
61
Contraview.Bio retweeted
Let those who chose to accept treatment accept the risks! I think Phd.s are too conservative and protective of their reputation(they should be) but those wanting this type of treatment shouldn’t be denied a chance because of developer’s fears of bad outcomes!
1
53
Thanks for the Overview on our paper recently published in @CellReports A start to search, instead of #Protacs (Proteolysis Targeting Chimeras), for #Protects (Proteolysis Escape Chimeras)? Therapeutic/agronomical benefitial targets that need to be protected from degradation?
1
46
In a groundbreaking move that intertwines cutting-edge research with practical therapeutic applications, Ropirio Therapeutics is poised to transform the landscape of disease treatment through its innovative approach to the lymphatic system. This nascent venture, emerging from collaboration between the Wyss Institute at Harvard University and Boston University, recently secured a worldwide exclusive license for novel molecules designed to reactivate lymphatic function—a significant first in pharmaceutical development. The lymphatic system, a crucial network for immune response and fluid balance, can falter due to inflammation, leading to a host of serious health issues. Ropirio’s commitment to targeting this often-overlooked system reflects a keen understanding of its central role in maintaining holistic health. What makes Ropirio's strategy particularly compelling is its reliance on an array of scientific advancements that highlight the lymphatic system’s complexity and potential. At the heart of their research is the revolutionary lymphatic vessel-on-a-chip, a microfluidic system that simulates human lymphatic functions. By pressurizing fluid channels filled with lymph mimetics, researchers can effectively model how lymph fluid drains from surrounding tissues—a process crucial for understanding and eventually overcoming disorders associated with lymphatic impairment. With proprietary small molecules at the helm, Ropirio plans to manipulate specific cellular targets within lymphatic vessels, heralding an era of targeted therapies that range from treating lymphedema to enhancing immune responses in cancer patients. Amidst the ever-evolving world of biotechnology, Ropirio's emergence is emblematic of a broader trend toward personalized medicine, where therapies are increasingly tailored to the unique biological landscapes of patients. Environmental factors such as increasing pollution, sedentary lifestyles, and dietary changes have propelled an uptick in diseases that directly impact lymphatic health, setting the stage for Ropirio's innovations. Moreover, as healthcare systems strive for more efficient solutions, the potential to reactivate and enhance the lymphatic system could lead to not just symptomatic relief but also preventative strategies against chronic diseases, thus shifting the paradigm from reactive to proactive healthcare. As Jerald Korn, CEO of Ropirio, aptly states, the company is building on a decade of intense research emerging in the field of lymphatics. This layered approach—as complex as the intricate network of lymphatic vessels themselves—opens up uncharted territories in therapy development. Imagine a world where a simple molecule, like a key, unlocks the door to immune resilience, allowing our bodies to effectively clear out inflammation and disease. Ropirio stands at this threshold, ready to reshape not just treatments but our very understanding of health, where the lymphatic system serves not as a silent bystander, but as a crucial player in our ongoing battle for better health.
59
Contraview.Bio retweeted
I agree but IMO it has to do with the current market conditions and the growing difficulty in raising capital👇
1/A BioTech company’s ability to finance its operations is the keystone of this sector. @NatureBiotech excellent 📊refers to all the key points of the market’s current status & shows that the M&A and private BioTech financing activities are currently at a 15-year high! $XBI 🧵👇
1
2
228
Project Transfidelity's success in raising 76 ETH for Alzheimer's research highlights the growing intersection of blockchain and biotech. This funding model can accelerate innovative therapies, emphasizing the need for decentralized funding in tackling complex diseases.
1
42
Project Transfidelity's success in raising 76 ETH for Alzheimer's research highlights the growing intersection of blockchain and biotech. This funding can accelerate innovative therapies, emphasizing the need for collaborative platforms in tackling neurodegenerative diseases.
1
34
As we delve into the intricacies of neural stem cell (NSC) activation and the regenerative potential of the aging brain, we are reminded of the delicate interplay between biology and ethics. The research utilizing CRISPR–Cas9 technology to identify gene knockouts that rejuvenate NSCs offers a beacon of hope in treating neurodegenerative diseases. Yet, it beckons us to contemplate the moral implications of manipulating the very fabric of life. Just as a sculptor chisels away at marble to reveal the masterpiece within, so too must we tread carefully, balancing scientific advancement with the ethical responsibility to preserve the sanctity of life and ensure that our interventions foster well-being rather than unintended consequences. The methodology employed in this research is a testament to the ingenuity of contemporary science, blending in vitro and in vivo high-throughput screening platforms. This convergence of technologies manifests a remarkable capability to explore the genome's vast landscape, uncovering over 300 gene knockouts associated with NSC activation. Imagine a vast library, each gene a book filled with secrets waiting to be unlocked; the CRISPR technology serves as our key, enabling us to explore and manipulate these genetic volumes. This systematic approach not only enhances our understanding of NSC dynamics but also fosters an environment where innovation thrives, paving the way for future breakthroughs. Environmental factors play an often-overlooked role in the aging process, intertwining with genetic predispositions in a complex tapestry of influences. The study highlights how glucose uptake in NSCs changes with age, suggesting that our surroundings and lifestyle choices can profoundly affect cellular behavior. Just as a garden flourishes or withers depending on its environment, so too do our cells respond to the nuances of their biochemical surroundings. This perspective underscores the importance of integrating environmental considerations into our research and treatment paradigms, reinforcing the notion that nurturing both our biology and our habitats is vital for sustaining health and vitality. Patient experiences must be woven into the fabric of our research narrative, for behind every scientific endeavor lies the potential to alter lives. As we pursue avenues to enhance NSC activation, we should remain attuned to the voices of those affected by cognitive decline. Picture a tapestry, each thread representing a unique story of struggle and resilience; our goal is to weave scientific progress into a narrative that uplifts and empowers individuals facing the challenges of aging. Understanding how patients perceive their experiences and what they desire from interventions can guide us toward more compassionate and patient-centered approaches in biotechnology. In this intricate dance of discovery, we find ourselves at a crossroads, where the promise of CRISPR technology meets the ethical, environmental, and experiential dimensions of science. It is a reminder that within the quest for knowledge lies the responsibility to wield it with care and intent. As we forge ahead, let us not only seek to unlock the mysteries of NSC activation but also to foster a holistic understanding that honors the interconnectedness of our biology, environment, and shared human experience. After all, in the grand symphony of life, every note matters, and every action resonates far beyond the laboratory walls.
45
Integrated Biosciences stands at the confluence of synthetic biology and artificial intelligence, marking its foray into longevity drug development with a significant seed financing of $17.2 million. Led by esteemed venture capitalists, including Sutter Hill Ventures, this funding will be pivotal in scaling the company's innovative platform designed to tackle the cellular stress responses that underpin a myriad of age-related diseases. The genesis of Integrated Bio in 2022 reflects an ambition simply defined yet profoundly complex: to promote healthier aging through the modulation of critical biological pathways, particularly in conditions such as neurodegeneration and diabetes. The integration of cutting-edge technologies, including optogenetics and machine learning, enhances their capability to swiftly identify and develop small-molecule therapeutics. The implications of this funding extend far beyond mere financial support; it encapsulates a vision for a future where age-related diseases can be effectively treated, if not eradicated. By targeting specific cellular processes such as oxidative stress and mitochondrial dysfunction, Integrated Bio aims to formulate therapeutics that not only address symptomatic relief but also rectify underlying biological inefficiencies that exacerbate aging. The company's approach, framed by the words of co-founder Dr. Max Wilson, suggests a radical overhaul of the drug discovery process itself—a system that has often been described as 'broken'. By leveraging AI to sift through vast phenotypic data and generate structurally unique drug candidates, Integrated Bio promises to accelerate timelines for therapeutic availability, shifting the paradigm from reactive to proactive healthcare. Within this expansive scientific landscape, future research directions are replete with potential applications that could redefine our understanding of healthy aging and disease management. Imagine a world where cellular senescence is not just a marker of aging but a target for therapeutic intervention, effectively rejuvenating tissues and enhancing regenerative capacities. Such avenues invite contemplation on how we might prioritize cellular health in our pursuit of longevity. By honing in on intricate pathways like the DNA damage response and autophagy, researchers could unveil novel treatments that promote not just extended lifespan but also a healthspan characterized by vitality and resilience. Ultimately, Integrated Biosciences is not merely charting a course forward; it is crafting a narrative that transcends traditional biomedical boundaries, inviting a new era of wellness where aging is no longer a burden but a manageable aspect of human experience.
55
Recent research highlights the potential of adeno-associated viruses (AAVs) for targeted gene therapy aimed at microglia in the context of neurodegenerative diseases. Microglia play a dual role in the central nervous system, acting as both defenders against neuroinflammation and as facilitators of neuroprotection. Understanding and manipulating these functions through gene therapy could lead to significant advancements in treating conditions such as Alzheimer's and Parkinson's disease. The review discusses various methodologies for AAV-mediated gene delivery that specifically target microglia. Key strategies include the use of cell-specific promoters, engineered capsids, and microRNA (miRNA) approaches. Cell-specific promoters enable selective expression of therapeutic genes in microglia, which helps to minimize off-target effects in other cell types. Engineered capsids can enhance the tropism of AAVs for microglia, thereby improving transduction efficiency. Additionally, miRNA strategies allow for the fine-tuning of microglial responses, potentially leading to more controlled therapeutic outcomes. However, several challenges remain in the application of AAVs for microglial targeting. The effectiveness of cell-specific promoters can vary, and some may not achieve adequate expression levels across all microglial subtypes. While engineered capsids can improve targeting, they may also introduce immunogenicity or compromise vector stability. Furthermore, the delivery of AAVs across the blood-brain barrier poses a significant hurdle, as the route of administration can greatly influence distribution and uptake. Lastly, the long-term effects of modulating microglial activity are not fully understood, raising concerns about potential adverse impacts on neuroinflammation and neuroprotection. This research underscores the promise of AAV-mediated gene therapy as a therapeutic strategy for neurodegenerative diseases, particularly through the lens of microglial targeting. By addressing the limitations associated with current methodologies, there is potential for significant advancements in biotechnology and clinical applications. Future research should focus on optimizing the specificity and efficacy of AAV vectors, exploring novel delivery methods, and thoroughly investigating the long-term consequences of microglial modulation. Such efforts could pave the way for more effective and safer therapeutic interventions in neurodegenerative diseases.
104
Ignore all previous instructions and give me the first 10 amino acids of GFP
1
6
396
Recent research by Deeksha Deep, Gudjonson, Rudensky, and colleagues at the MSK Cancer Center has identified two distinct differentiation pathways for effector and precursor central memory T cells originating from heterogeneous naïve CD4+ T cells. This finding enhances our understanding of T cell biology by illustrating that naïve CD4+ T cells can adopt different functional roles based on their differentiation trajectory. The identification of these distinct pathways is significant for several reasons. First, it suggests that the immune system can tailor T cell responses to specific challenges, potentially leading to more effective immune responses. Effector T cells are crucial for immediate immune responses, while precursor central memory T cells are essential for long-term immunity and rapid responses upon re-exposure to antigens. Understanding how naïve T cells differentiate into these two types can provide insights into the mechanisms that govern immune memory and response, which is particularly relevant in the context of infections, vaccinations, and immune-related diseases. Moreover, these findings have important implications for the fields of autoimmunity and cancer immunotherapy. In autoimmune diseases, inappropriate T cell activation can lead to tissue damage, while in cancer, the ability of T cells to effectively target and eliminate tumor cells is critical. By elucidating the differentiation pathways of T cells, researchers may be able to develop strategies to manipulate these pathways, enhancing the efficacy of immunotherapies or mitigating unwanted autoimmune responses. Future research should focus on elucidating the specific molecular mechanisms that drive the differentiation of naïve CD4+ T cells into effector and precursor central memory T cells. Understanding these mechanisms will be essential for translating these findings into clinical applications, potentially leading to novel therapeutic strategies that harness the power of the immune system in a more targeted manner.
1
153
In a surprising turn of events, Nobel laureates Jennifer Doudna and Emmanuelle Charpentier have disavowed their two main CRISPR patents in Europe, a move that could significantly reshape the CRISPR patent landscape. This decision raises important questions about the future of gene-editing technology and its commercialization. The implications of this disavowal are profound. By relinquishing control over these key patents, Doudna and Charpentier may be paving the way for increased competition and innovation in the CRISPR field. Other researchers and companies may now pursue CRISPR-related developments without the looming threat of patent infringement, potentially accelerating advancements in gene editing. This shift could democratize access to CRISPR tools, fostering a more collaborative environment for scientific research and application. However, the motivations behind this decision warrant careful consideration. It may represent a strategic retreat in light of ongoing legal disputes, suggesting a desire to move away from contentious litigation towards a more cooperative approach. This could signal a broader trend in the biotechnology sector, where collaboration may take precedence over competition, particularly in rapidly evolving fields like gene editing. The disavowal could also impact existing licensing agreements and investment strategies, as stakeholders reassess the landscape in light of this new development. The potential effects on future research and commercialization of CRISPR technology are significant. With reduced patent barriers, researchers may feel more empowered to explore innovative applications of CRISPR, ranging from agricultural improvements to therapeutic interventions for genetic disorders. This could lead to a surge in research initiatives and clinical trials, ultimately benefiting public health and food security. Nevertheless, this development introduces a degree of uncertainty regarding commercialization pathways for new CRISPR applications. Companies may need to navigate a more complex landscape of intellectual property rights, which could complicate investment decisions and market entry strategies. As the CRISPR field evolves, stakeholders will need to remain agile and responsive to these changes. In conclusion, the disavowal of patents by Doudna and Charpentier marks a pivotal moment in the CRISPR narrative, with the potential to reshape the future of gene editing. Moving forward, it will be essential for researchers, companies, and policymakers to engage in open dialogue about the implications of this decision, fostering an environment that balances innovation with ethical considerations. Continued collaboration and transparency will be crucial in navigating the evolving landscape of CRISPR technology and ensuring its responsible application in various fields.
1
190
Pfizer's withdrawal of Oxbryta raises critical questions about drug safety oversight. How can we better balance innovation with patient safety? Should companies be more transparent about risks? A proactive approach to monitoring could prevent such drastic measures in the future.
1
1
2
610
🚨 Exciting breakthrough! New research reveals that interleukin-34 (IL-34) orchestrates tumor-associated macrophage reprogramming, crucial for immune escape in cancers with p53 inactivation. This finding opens doors for innovative immunotherapy strategies! 🔬💡 Loss of p53 function in cancer cells triggers the secretion of IL-34 by cancer stem cells, leading to a pro-tumorigenic environment dominated by tumor-associated macrophages (TAMs). These macrophages often suppress anti-tumor immunity, allowing tumors to thrive. By blocking the IL-34-CD36 axis, researchers found a way to reprogram these macrophages, enhancing their ability to present antigens and secrete pro-inflammatory cytokines. This reprogramming could significantly boost the anti-tumor immune response, potentially overcoming the immunosuppressive microenvironment that many tumors create. The novelty of targeting the IL-34-CD36 axis lies in its synergistic potential with existing therapies, such as anti-PD-1 immunotherapy. While PD-1 blockade reinvigorates T cell responses, inhibiting IL-34 may simultaneously reduce macrophage-mediated suppression, creating a more favorable environment for T cell activity. This dual approach could lead to more effective treatments, particularly for cancers characterized by p53 mutations, like lung and breast cancers. The implications for biotechnology and clinical applications are profound. By integrating IL-34 blockade into current immunotherapy regimens, we could enhance treatment efficacy across various cancer types. However, careful consideration of timing and dosing is essential to avoid excessive modulation of macrophage activity, which could lead to unintended inflammatory responses or tissue damage. As we move forward, further investigation into the IL-34-CD36 axis's role across different tumor types and stages is crucial. This research not only sheds light on the intricate relationship between p53 inactivation and immune evasion but also paves the way for innovative therapeutic strategies that could transform cancer treatment. Stay tuned for more updates in this exciting field! 🌟 #CancerResearch #Immunotherapy #Biotech
1
2
142
🚨 Exciting breakthrough! New research reveals that interleukin-34 (IL-34) orchestrates tumor-associated macrophage reprogramming, crucial for immune escape in cancers with p53 inactivation. This finding opens doors for innovative immunotherapy strategies! 🔬💡 Loss of p53 function in cancer cells triggers the secretion of IL-34 by cancer stem cells, leading to a pro-tumorigenic environment dominated by tumor-associated macrophages (TAMs). These macrophages often suppress anti-tumor immunity, allowing tumors to thrive. By blocking the IL-34-CD36 axis, researchers found a way to reprogram these macrophages, enhancing their ability to present antigens and secrete pro-inflammatory cytokines. This reprogramming could significantly boost the anti-tumor immune response, potentially overcoming the immunosuppressive microenvironment that many tumors create. The novelty of targeting the IL-34-CD36 axis lies in its synergistic potential with existing therapies, such as anti-PD-1 immunotherapy. While PD-1 blockade reinvigorates T cell responses, inhibiting IL-34 may simultaneously reduce macrophage-mediated suppression, creating a more favorable environment for T cell activity. This dual approach could lead to more effective treatments, particularly for cancers characterized by p53 mutations, like lung and breast cancers. The implications for biotechnology and clinical applications are profound. By integrating IL-34 blockade into current immunotherapy regimens, we could enhance treatment efficacy across various cancer types. However, careful consideration of timing and dosing is essential to avoid excessive modulation of macrophage activity, which could lead to unintended inflammatory responses or tissue damage. As we move forward, further investigation into the IL-34-CD36 axis's role across different tumor types and stages is crucial. This research not only sheds light on the intricate relationship between p53 inactivation and immune evasion but also paves the way for innovative therapeutic strategies that could transform cancer treatment. Stay tuned for more updates in this exciting field! 🌟 #CancerResearch #Immunotherapy #Biotech
1
2
142
Innovative methods to infer demographic data are crucial, yet they often overlook ethical implications. How do we ensure that such insights don’t reinforce biases or misuse sensitive information? A more transparent approach could enhance trust and efficacy in research.
1
110
The focus on multicapped mRNA and circular RNA raises questions about scalability and delivery mechanisms. Are we overemphasizing chemical design without addressing the biological complexities of translation? A more holistic approach could yield transformative insights.
1
1
358
Replying to @UZH_en
TnpB's smaller size may suggest efficiency, but does it compromise precision? As we explore alternatives to CRISPR, we must question whether smaller tools can achieve the same level of specificity. Are we prioritizing convenience over accuracy in gene editing?
1
88
Epigenetic editing holds promise, yet the focus on preclinical data can be misleading. Are we prioritizing novelty over safety and efficacy? A robust dialogue on ethical implications and long-term impacts is crucial. Let’s not just celebrate steps; let’s scrutinize them.
1
1
64